Showing 661-670 of 1865 results for "".
- INT for Melanoma 'Coming Very Fast,' Dr. Joel Claveau Says at Noah Worcester Meetinghttps://practicaldermatology.com/news/INT-Melanoma-Coming-Very-Fast-Dr-Joel-Claveau-Says-Noah-Worcester-Meeting/2475044/The next big thing in melanoma treatment may be individualized neoantigen therapy (INT)—according to Joel Claveau, MD, in a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec. “It’s almost rocket science, but it’s really coming very fast,” Dr. Claveau
- From ASLMS 2025: Dr. Joel Cohen Highlights New Fractional Laser Techniques, Including Laser-enabled Tissue Coringhttps://practicaldermatology.com/news/from-aslms-dr-joel-cohen-highlights-new-fractional-laser-techniques-for-scars-at-aslms/2474327/During a fractional laser section of the recent program of the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, board-certified dermatologist, Mohs surgeon, and laser expert Joel L. Cohen, MD, FAAD, FACMS, presented clinical insights into fractional laser us
- Journey Medical's Claude Maraoui to Speak in 'Fireside Chat' at ROTH Conferencehttps://practicaldermatology.com/news/Journey-Medicals-Claude-Maraoui-Speak-Fireside-Chat-ROTH-Conference/2471608/Journey Medical Corporation president and CEO Claude Maraoui will participate in a “fireside chat” Tuesday, March 18, at the 37th Annual ROTH Conference in Dana Point, California, the company announced. Maraoui’s session will be held at 12:30 p.m. PT, and a webcast will be available for ap
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- JAK Inhibitors' Applications Continue to Expandhttps://practicaldermatology.com/news/JAK-Inhibitors-Applications-Continue-Expand/2471523/While JAK inhibitors have become widely popular for several common skin diseases, their potential for other indications remains vast, and Ruth Ann Vleugels, MD, MPA, MPH, FAAD, highlighted some of these in “JAK Inhibitors for Lupus, Dermatomyositis, and SAVI” at the 2025 American Academy of Derma
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- JOYA Launches Skin Cancer Prevention, Anti-Aging Employee Benefit Platformhttps://practicaldermatology.com/news/joya-launches-skin-cancer-prevention-anti-aging-employee-benefit-platform/2468435/JOYA, the first employee skin health and wellness benefit platform, announced its emergence from stealth mode with $5 million in seed funding from LUX Capital, Mosaic General Partnership, Arsama Trust, and Joyance Partners. The funding will support team expansion, product development, mar
- Researchers Analyze Social Media Posts on JAK Inhibitorshttps://practicaldermatology.com/news/researchers-analyze-social-media-posts-jak-inhibitors/2468227/An analysis of social media posts concluded that patients are most concerned about the efficacy and side effects of JAK inhibitors and issues regarding access to them, according to a new Archive of Dermatological Research article by members of the University of Nebraska Medical Center’s Departmen
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis